Latest Medical News from Russia

Thanks to government and private investment, Russia has created comprehensive nuclear medicine infrastructure over the past 20 years, a network of PET/CT diagnostic centers, SPECT/CT facilities at major multidisciplinary clinics, and "hot beds" for radiopharmaceutical treatment. This infrastructure is followed by radiopharmaceutical development and clinical trials, and theranostics development available in only a few countries. Read the full analysis on Marus Media.

For blood cancers that don't respond well to standard treatments, oncologists and hematologists are turning to the personalized CAR-T approach (chimeric antigen receptor T-cell therapy). This treatment creates modified T-cells from a patient's own cells that can destroy tumor cells. This overview from Marus Media provides the current status of the technology and its availability for medical tourists.

Ramiclinic Residence has opened on Krestovsky Island in St. Petersburg, a clinic combining aesthetic medicine with luxury-class service. The project develops the "medical residence" concept, where patients can receive a comprehensive solution, from diagnosis and surgery to rehabilitation, in one place. Breast oncologist, plastic surgeon, and Deputy Chief Medical Officer of Ramiclinic Residence Anton Telishevsky discusses the business model, safety principles, and medical expertise.

During operations to remove gliomas – brain tumors – one of the surgeon's main tasks is to determine the tumor boundary so as to remove the maximum number of malignant cells without damaging healthy tissue. Specialists from the Privolzhsky Research Medical University have developed a macro-FLIM (fluorescence lifetime imaging microscopy) method that allows for rapid analysis of removed tissue samples during surgery and identification of tumor cells by their "metabolic fingerprint."

Russia's Ministry of Health has issued a registration certificate for the first Russian generic of Translarna (ataluren) from PTC Therapeutics. The product is Ataluren, manufactured by the company Geropharm. Development of a domestic version of the high-cost originator drug will expand access to therapy for pediatric patients with Duchenne muscular dystrophy who have specific genetic mutations.

Russia's Ministry of Health has authorized the Chinese pharmaceutical company Dizal Pharma to conduct Phase III clinical trials of birlentinib, an investigational drug for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. The agent targets cases in which malignant cells have acquired resistance to standard BTK inhibitor therapies such as ibrutinib.

One of Russia's leading manufacturers of prosthetics and wheelchairs, Motorica, will begin training prosthetic limb engineering technologists. This specialty is considered one of the most in-demand in the global orthopedic and prosthetic services market: in Russia, for example, the prosthetist shortage is 2,300 people.

Forty years ago, the world faced an epidemic dubbed "the plague of the 20th century." Today we observe how the history of fighting AIDS takes on new contours: from daily struggle for life, to control strategies, from stigma, to conscious acceptance. On World AIDS Day, Marus Media traces this evolutionary path, from despair to hope, from survival to full life.

Pembrolizumab manufactured by Biocad has demonstrated efficacy in the treatment of melanoma, according to the results of a clinical trial conducted in Cuba. An objective response was achieved in 34% of patients, with complete tumor disappearance observed in 10,6% of study participants.